{"groups":[{"description":"Panobinostat (LBH589): 20 mg by mouth three (3) times per week, every other week, of a 28-day schedule.\n\nPanobinostat: Maintenance therapy dosing as outlined in Cohorts A and B.","id":"FG000","title":"Cohort A: Maintenance Therapy"},{"description":"Panobinostat (LBH589): 10 mg by mouth daily for seven (7) days, every other week, of a 28-day schedule.\n\nPanobinostat: Maintenance therapy dosing as outlined in Cohorts A and B.","id":"FG001","title":"Cohort B: Maintenance Therapy"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"15"},{"groupId":"FG001","numSubjects":"15"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"15"},{"groupId":"FG001","numSubjects":"15"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}